



Saleem, M., & Welsh, G. I. (2019). Podocyte Rho GTPases: new therapeutic targets for Nephrotic Syndrome? *F1000Research*.  
<https://doi.org/10.12688/f1000research.20105.1>

Publisher's PDF, also known as Version of record

License (if available):  
CC BY

Link to published version (if available):  
[10.12688/f1000research.20105.1](https://doi.org/10.12688/f1000research.20105.1)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the final published version of the article (version of record). It first appeared online via F1000Research at <https://f1000research.com/articles/8-1847>. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>



## REVIEW

# Podocyte RhoGTPases: new therapeutic targets for nephrotic syndrome? [version 1; peer review: 2 approved]

Moin A. Saleem , Gavin I. Welsh 

Bristol Renal, Bristol Medical School, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol, BS1 3NY, UK

**v1** **First published:** 04 Nov 2019, 8(F1000 Faculty Rev):1847 (<https://doi.org/10.12688/f1000research.20105.1>)  
**Latest published:** 04 Nov 2019, 8(F1000 Faculty Rev):1847 (<https://doi.org/10.12688/f1000research.20105.1>)

## Abstract

Podocytes, or glomerular epithelial cells, form the final layer in the glomerular capillary wall of the kidney. Along with the glomerular basement membrane and glomerular endothelial cells, they make up the glomerular filtration barrier which allows the passage of water and small molecules and, in healthy individuals, prevents the passage of albumin and other key proteins. The podocyte is a specialised and terminally differentiated cell with a specific cell morphology that is largely dependent on a highly dynamic underlying cytoskeletal network and that is essential for maintaining glomerular function and integrity in healthy kidneys. The RhoGTPases (RhoA, Rac1 and Cdc42), which act as molecular switches that regulate actin dynamics, are known to play a crucial role in maintaining the cytoskeletal and molecular integrity of the podocyte foot processes in a dynamic manner. Recently, novel protein interaction networks that regulate the RhoGTPases in the podocyte and that are altered by disease have been discovered. This review will discuss these networks and their potential as novel therapeutic targets in nephrotic syndrome. It will also discuss the evidence that they are direct targets for (a) steroids, the first-line agents for the treatment of nephrotic syndrome, and (b) certain kinase inhibitors used in cancer treatment, leading to nephrotoxicity.

## Keywords

Podocyte, RhoGTPases, Nephrotic Syndrome.

## Open Peer Review

**Reviewer Status**  

	Invited Reviewers	
	1	2
<b>version 1</b> published 04 Nov 2019		

**F1000 Faculty Reviews** are written by members of the prestigious **F1000 Faculty**. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

- 1 **Shreeram Akilesh**, University of Washington, Seattle, Washington, USA
- 2 **Robert Spurney**, Duke University Health System, Durham, USA  
Durham VA Medical Center, Durham, USA  
**Gentzon Hall**, Duke University Health System, Durham, USA  
Durham VA Medical Center, Durham, USA

Any comments on the article can be found at the end of the article.

**Corresponding author:** Gavin I. Welsh ([G.I.Welsh@bristol.ac.uk](mailto:G.I.Welsh@bristol.ac.uk))

**Author roles:** Saleem MA: Writing – Original Draft Preparation; Welsh GI: Writing – Original Draft Preparation

**Competing interests:** No competing interests were disclosed.

**Grant information:** Work in the authors' laboratory is sponsored by the Medical Research Council, Kidney Research UK and the Nephrotic Syndrome Trust.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2019 Saleem MA and Welsh GI. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Saleem MA and Welsh GI. **Podocyte RhoGTPases: new therapeutic targets for nephrotic syndrome?** [version 1; peer review: 2 approved] F1000Research 2019, 8(F1000 Faculty Rev):1847 (<https://doi.org/10.12688/f1000research.20105.1>)

**First published:** 04 Nov 2019, 8(F1000 Faculty Rev):1847 (<https://doi.org/10.12688/f1000research.20105.1>)

## Introduction

The kidney is vital for the maintenance of water and electrolyte homeostasis and for the removal of waste metabolites from the blood while retaining or reabsorbing useful components. The filtration unit of the kidney, the glomerulus is composed of a bundle of capillaries, which are highly permeable to water yet can retain larger macromolecules while selectively allowing passage of solutes. This selectivity is achieved by the action of the glomerular filtration barrier, which comprises the glomerular basement membrane, glomerular endothelial cells and glomerular epithelial cells—or podocytes<sup>1</sup>. Terminally differentiated epithelial cells, podocytes are critical in preventing protein passage across the filtration barrier. They have branching and interdigitating processes, and filtration takes place through slits between these processes. A critical component of the filtration barrier, the slit diaphragm is an ultra-thin zipper-like structure that bridges the gap between interdigitating podocyte foot processes. It is a cell junction and signalling complex that is essential for regulating podocyte cytoskeletal dynamics<sup>2</sup>.

Podocytes have a remarkably elaborate and highly specialised morphology that critically depends on an underlying network of dynamic and interconnected actin and microtubule polymers which allow them to respond rapidly to environmental changes to maintain a healthy filtration barrier<sup>3,4</sup>. Damage to this unique cytoskeletal architecture is a hallmark of glomerular disease, and the importance of correct regulation of this process can be demonstrated by the fact that a number of human nephrotic syndromes (NS) are caused by genetic mutations coding for podocyte-specific proteins or proteins that seem only dysfunctional within the podocyte and that are associated with the slit diaphragm or directly link it to the podocyte actin cytoskeleton<sup>5</sup>. Therefore, an understanding of how the cellular architecture of the podocyte is regulated in health and how this is disrupted in disease is essential. Recent work, which will be discussed in this review, has highlighted the crucial role of the RhoGTPases—which act as molecular switches regulating actin dynamics—in the unique biology of the podocyte and the pathogenesis of glomerular diseases. Excitingly, recent work has also suggested that pathways that regulate RhoGTPases in the podocyte are the site of action for steroids, the main first-line treatment for NS, thus identifying novel biological pathways that can be targeted therapeutically<sup>6–8</sup>.

The RhoGTPases RhoA, Rac1 and Cdc42 act as molecular switches—cycling between an active GTP-bound form and an inactive GDP-bound form—that are crucial regulators of several cellular processes, including actin and microtubule cytoskeletal dynamics, cell morphogenesis and cell migration<sup>9</sup>. The activity of these proteins is tightly regulated by a variety of guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs) which act to control the ratio of the GTP- and GDP-bound forms<sup>9</sup>. There is substantial evidence, reviewed previously<sup>10</sup>, that the RhoGTPases play a crucial role in the regulation of podocyte biology whereby RhoA activation increases in actin stress fibres promoting a contractile phenotype whilst Rac1/Cdc42 activation increases lamellipodia/filopodia

formation promoting cell motility<sup>11</sup>. It is known that there is crosstalk between the GTPases and that tight regulation of their activities is crucial for maintaining a healthy podocyte phenotype as changes to the balance of the activity of the small GTPases lead to hypo- or hyper-motility of podocytes resulting in proteinuria<sup>7</sup>. This was recently demonstrated in drosophila nephrocytes, which are structurally and functionally homologous to podocytes, where a tight balance of Rac1 and Cdc42 activity is essential to maintain the specialised architecture and function of this cell<sup>12</sup>. The RhoGTPases appear to have different roles in specific disease states, and controversy remains as to the exact role that alterations in their activity play in disease pathogenesis<sup>11</sup>. For example, alterations in Rac1 activity have been shown to be both beneficial and detrimental to the podocyte and this may depend on the type of podocyte injury involved<sup>11</sup>. Inducible Rac1 activation specifically in podocytes in mice induces foot process effacement, proteinuria and the spectrum of NS ranging from minimal change disease to focal segmental glomerulosclerosis (FSGS)<sup>13,14</sup>. In contrast, Rac1 has also been shown to be important for glomerular repair as podocyte-specific knock-out resulted in increased glomerulosclerosis via suppression of mammalian target of rapamycin (mTOR) activity in injured podocytes<sup>15</sup>.


The RhoGTPases are known to regulate or are regulated by a number of factors implicated in NS, such as TRPC5, TRPC6 and suPAR<sup>16–19</sup>. Mutation analysis of patients with NS has recently revealed novel functional networks which regulate the GTPases and which are altered in disease-causing changes to the activity of these proteins. Braun *et al.* reported disease-causing mutations in genes encoding the nuclear pore complex proteins NUP107, NUP85 and NUP133 in patients with steroid-resistant NS and demonstrated that knockdown of any of these three proteins in podocytes led to the activation of Cdc42<sup>20</sup>. Ashraf *et al.* identified mutations in six different genes (*MAGI2*, *TNS2*, *DCL1*, *CDK20*, *ITSN1* and *ITNS2*) which result in partially treatment-sensitive NS<sup>7</sup>. These proteins interact and form complexes which are involved in the regulation of the RhoGTPases, especially RhoA and Cdc42<sup>7</sup>. *MAGI2*, *TNS2*, *DCL1* and *CDK20* form complexes that regulate RhoA whilst *ITSN1* and *2* are GEFs for Cdc42. *MAGI2* also forms a complex with the Rap1 GEF, RapGEF2, regulating Rap1 and this complex is lost in the presence of the *MAGI2* mutations<sup>21</sup>. Importantly, glucocorticoids, which are the standard treatment for NS in children, have been shown to act directly on the podocyte<sup>22</sup> and a potential mechanism for their beneficial effect has been shown to be via these RhoGTPase regulatory complexes<sup>7</sup>. In agreement with these findings that the mode of action of steroids may be via direct action on the podocyte to regulate the RhoGTPases, McCaffrey *et al.* have demonstrated that dexamethasone reduces the podocyte activity of Rac1, thereby increasing barrier function<sup>8</sup>. However, modelling *MAGI2* mutations in zebrafish suggest that the effectiveness of steroids in treating alterations in RhoGTPase activity depends on the specific genetic mutation involved and so unravelling the specific action and targets of these agents will be crucially important<sup>23</sup>. Maeda *et al.* recently delineated another protein pathway regulating RhoGTPase activity in the podocyte, centred on Ca<sup>2+</sup>/calmodulin-dependent kinase 4 (CaMK4)/synaptotagmin,

as a potential target for treating podocytopathies such as NS<sup>24</sup>. Prevention of the degradation of the actin organising protein synaptopodin and subsequent stabilisation of the RhoA/Cdc42 signalling pathway by the direct action of the anti-proteinuric drug cyclosporin A on the podocyte have been reported<sup>25</sup>. It has since been shown that increased expression of CaMK4, which is seen in FSGS, both alters the expression of Rac1 and RhoA and leads to the phosphorylation of the scaffold protein 14-3-3. Phosphorylation of 14-3-3 results in the proteolytic cleavage of the actin organising protein synaptopodin because of a loss of interaction between the two proteins, causing enhanced Rac1 signalling, decreased RhoA activity and increased podocyte motility<sup>24,26</sup>. A CaMK4 inhibitor ameliorated synaptopodin degradation, alterations in RhoGTPase activity and changes to motility in human podocytes. Furthermore, podocyte-specific targeting of this inhibitor prevented and reversed podocyte injury and renal disease in both the adriamycin mouse model of FSGS and mice exposed to lipopolysaccharide-induced podocyte injury<sup>24</sup>. These results suggest that targeting the pathways regulating or regulated by the GTPase may be a novel therapeutic area for glomerular disease. Conversely, recent data suggested that kinase inhibitors such as dasatinib, used in clinical oncology, may have nephrotoxic effects by affecting RhoGTPase signalling in the podocyte<sup>27</sup>. Therefore, a clear delineation of the complex network of protein interactions centred on the RhoGTPases in the podocyte and how they alter the specialised biology of this cell is becoming increasingly important.

In addition to the pathways already detailed, several other proteins have been identified to be important regulators of the GTPases in podocytes. For example, ARHGAP24 regulates Rho/Rac signalling balance in podocytes and mutations in this protein are associated with familial FSGS<sup>28</sup>. Mutations in ARHGDI (a GDI for Cdc42 and Rac1), KANK2, ARHGEF17 and FAT1 all result in altered RhoGTPase activity and cause NS<sup>29–33</sup>. SLIT-ROBO pGTPase-activating protein 2a (SRGAP2a) suppresses podocyte motility through inactivating RhoA and Cdc42 and is downregulated in patients with kidney disease<sup>34</sup>.

Trio, a GEF for Rac1, is expressed in podocytes and is significantly upregulated in glomeruli of patients with FSGS<sup>35</sup>. Human FSGS-causing mutations in anillin have been shown to induce hyperactivation of both Rac1 and mTOR in podocytes<sup>36</sup>. Rac1 activity is also regulated via the kindlin-2–RhoGDIα–Rac1 signalling axis. Knockout of kindlin-2 resulted in hyperactivation of Rac1 via a reduction in RhoGDIα levels and an increased dissociation of this protein from Rac1, leading to podocyte cytoskeletal re-organisation, foot process effacement and massive proteinuria<sup>37</sup>. In addition, podocyte foot process effacement due to loss of kindlin-2 has been linked to increased RhoA activity and resulting changes to cortical actin structures, plasma membrane tension and focal adhesion function<sup>38</sup>. Rac1 activity is also regulated by the binding of RhoGDI to the actin regulatory protein, ezrin. The ezrin knockout mouse has significantly reduced Rac1 activity and is protected from injury-induced morphological changes<sup>39</sup>. CLIC5A, a chloride intracellular channel, stimulates podocyte Rac1 activity leading to the activation of both ezrin and the cytoskeleton regulator PAK1<sup>40</sup>.

These results suggest that clearly understanding the cellular network in health and disease that both regulate and are regulated by RhoGTPase activity will provide new therapeutic targets for NS. Indeed, small-molecule inhibitors targeting the RhoGTPases are already being developed in the cancer field and several drug targets have been suggested in the NS field, such as TRPC5, TRPC6 and suPAR, which either are known modulators of or are modulated by the RhoGTPases<sup>16–19,41</sup>. For example, inhibition of TRPC5 which is activated downstream of Rac1, leading to deleterious podocyte cytoskeleton remodelling, has been shown to ameliorate kidney disease in rat models of NS<sup>19</sup>. However, as detailed above, there is already evidence for the involvement of multiple interactions and pathways in maintaining the correct balance of activity of the RhoGTPases and these proteins work in concert with other GTPases such as dynamin to regulate podocyte phenotype<sup>42</sup>, so unpicking this complex network will not be an easy proposition (Figure 1).



**Figure 1.** Regulation of the RhoGTPases in the podocyte.



## References



1. Scott RP, Quaggin SE: **Review series: The cell biology of renal filtration.** *J Cell Biol.* 2015; **209**(2): 199–210.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Reiser J, Altintas MM: **Podocytes [version 1; peer review: 2 approved].** *F1000Res.* 2016; **5**: pii: F1000 Faculty Rev-114.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Garg P: **A Review of Podocyte Biology.** *Am J Nephrol.* 2018; **47** Suppl 1: 3–13.  
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Welsh GI, Saleem MA: **The podocyte cytoskeleton—key to a functioning glomerulus in health and disease.** *Nat Rev Nephrol.* 2011; **8**(1): 14–21.  
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Bierzynska A, Soderquest K, Koziell A: **Genes and podocytes - new insights into mechanisms of podocytopathy.** *Front Endocrinol (Lausanne).* 2015; **5**: 226.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. He FF, Chen S, Su H, *et al.*: **Actin-associated Proteins in the Pathogenesis of Podocyte Injury.** *Curr Genomics.* 2013; **14**(7): 477–84.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Ashraf S, Kudo H, Rao J, *et al.*: **Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment.** *Nat Commun.* 2018; **9**(1): 1960.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
8. McCaffrey JC, Webb NJ, Poolman TM, *et al.*: **Glucocorticoid therapy regulates podocyte motility by inhibition of Rac1.** *Sci Rep.* 2017; **7**(1): 6725.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
9. Haga RB, Ridley AJ: **Rho GTPases: Regulation and roles in cancer cell biology.** *Small GTPases.* 2016; **7**(4): 207–21.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Kistler AD, Altintas MM, Reiser J: **Podocyte GTPases regulate kidney filter dynamics.** *Kidney Int.* 2012; **81**(11): 1053–5.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Yu SM, Nissaisorakarn P, Husain I, *et al.*: **Proteinuric Kidney Diseases: A Podocyte's Slit Diaphragm and Cytoskeleton Approach.** *Front Med (Lausanne).* 2018; **5**: 221.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
12. Muraleedharan S, Sam A, Skaer H, *et al.*: **Networks that link cytoskeletal regulators and diaphragm proteins underpin filtration function in *Drosophila* nephrocytes.** *Exp Cell Res.* 2018; **364**(2): 234–42.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
13. Robins R, Baldwin C, Aoudjit L, *et al.*: **Rac1 activation in podocytes induces the spectrum of nephrotic syndrome.** *Kidney Int.* 2017; **92**(2): 349–64.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
14. Yu H, Suleiman H, Kim AH, *et al.*: **Rac1 activation in podocytes induces rapid foot process effacement and proteinuria.** *Mol Cell Biol.* 2013; **33**(23): 4755–64.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Asao R, Seki T, Takagi M, *et al.*: **Rac1 in podocytes promotes glomerular repair and limits the formation of sclerosis.** *Sci Rep.* 2018; **8**(1): 5061.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
16. Greka A, Mundel P: **Balancing calcium signals through TRPC5 and TRPC6 in podocytes.** *J Am Soc Nephrol.* 2011; **22**(11): 1969–80.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Peev V, Hahn E, Reiser J: **Unwinding focal segmental glomerulosclerosis [version 1; peer review: 3 approved].** *F1000Res.* 2017; **6**: 466.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Zeier M, Reiser J: **suPAR and chronic kidney disease—a podocyte story.** *Pflügers Arch.* 2017; **469**(7–8): 1017–20.  
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Zhou Y, Castonguay P, Sidhom EH, *et al.*: **A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models.** *Science.* 2017; **358**(6368): 1332–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
20. Braun DA, Lovric S, Schapiro D, *et al.*: **Mutations in multiple components of the nuclear pore complex cause nephrotic syndrome.** *J Clin Invest.* 2018; **128**(10): 4313–28.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
21. Zhu B, Cao A, Li J, *et al.*: **Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2.** *Kidney Int.* 2019; **96**(3): 642–55.  
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Xing CY, Saleem MA, Coward RJ, *et al.*: **Direct effects of dexamethasone on human podocytes.** *Kidney Int.* 2006; **70**(6): 1038–45.  
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Jobst-Schwan T, Hoogstraten CA, Kolvenbach CM, *et al.*: **Corticosteroid treatment exacerbates nephrotic syndrome in a zebrafish model of *magi2a* knockout.** *Kidney Int.* 2019; **95**(5): 1079–90.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
24. Maeda K, Otomo K, Yoshida N, *et al.*: **CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease.** *J Clin Invest.* 2018; **128**(8): 3445–59.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
25. Sever S, Schiffer M: **Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases.** *Kidney Int.* 2018; **93**(6): 1298–307.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
26. Buval L, Wallentin H, Sieber J, *et al.*: **Synaptopodin Is a Coincidence Detector of Tyrosine versus Serine/Threonine Phosphorylation for the Modulation of Rho Protein Crosstalk in Podocytes.** *J Am Soc Nephrol.* 2017; **28**(3): 837–51.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
27. Calizo RC, Bhattacharya S, van Hasselt JGC, *et al.*: **Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity.** *Nat Commun.* 2019; **10**(1): 2061.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
28. Akilesh S, Suleiman H, Yu H, *et al.*: **Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis.** *J Clin Invest.* 2011; **121**(10): 4127–37.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
29. Gee HY, Sadowski CE, Aggarwal PK, *et al.*: **FAT1 mutations cause a glomerulotubular nephropathy.** *Nat Commun.* 2016; **7**: 10822.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Gee HY, Saisawat P, Ashraf S, *et al.*: **ARHGDI mutations cause nephrotic syndrome via defective RHO GTPase signaling.** *J Clin Invest.* 2013; **123**(8): 3243–53.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
31. Gee HY, Zhang F, Ashraf S, *et al.*: **KANK deficiency leads to podocyte dysfunction and nephrotic syndrome.** *J Clin Invest.* 2015; **125**(6): 2375–84.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
32. Auguste D, Maier M, Baldwin C, *et al.*: **Disease-causing mutations of RhoGDI $\alpha$  induce Rac1 hyperactivation in podocytes.** *Small GTPases.* 2016; **7**(2): 107–21.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
33. Yu H, Artomov M, Brähler S, *et al.*: **A role for genetic susceptibility in sporadic focal segmental glomerulosclerosis.** *J Clin Invest.* 2016; **126**(3): 1067–78.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
34. Pan Y, Jiang S, Hou Q, *et al.*: **Dissection of Glomerular Transcriptional Profile in Patients With Diabetic Nephropathy: SRGAP2a Protects Podocyte Structure and Function.** *Diabetes.* 2018; **67**(4): 717–30.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
35. Maier M, Baldwin C, Aoudjit L, *et al.*: **The Role of Trio, a Rho Guanine Nucleotide Exchange Factor, in Glomerular Podocytes.** *Int J Mol Sci.* 2018; **19**(2): pii: E479.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. Hall G, Lane BM, Khan K, *et al.*: **The Human FSGS-Causing ANLN R431C Mutation Induces Dysregulated PI3K/AKT/mTOR/Rac1 Signaling in Podocytes.** *J Am Soc Nephrol.* 2018; **29**(8): 2110–22.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
37. Sun Y, Guo C, Ma P, *et al.*: **Kindlin-2 Association with Rho GDP-Dissociation Inhibitor  $\alpha$  Suppresses Rac1 Activation and Podocyte Injury.** *J Am Soc Nephrol.* 2017; **28**(12): 3545–62.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
38. Yasuda-Yamahara M, Rogg M, Frimmel J, *et al.*: **FERMT2 links cortical actin structures, plasma membrane tension and focal adhesion function to stabilize podocyte morphology.** *Matrix Biol.* 2018; **68–69**: 263–79.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
39. Hatano R, Takeda A, Abe Y, *et al.*: **Loss of ezrin expression reduced the susceptibility to the glomerular injury in mice.** *Sci Rep.* 2018; **8**: 4512.  
[Publisher Full Text](#) | [F1000 Recommendation](#)
40. Tavasoli M, Li L, Al-Momany A, *et al.*: **The chloride intracellular channel 5A stimulates podocyte Rac1, protecting against hypertension-induced glomerular injury.** *Kidney Int.* 2016; **89**(4): 833–47.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
41. Maldonado MdM, Dharmawardhane S: **Targeting Rac and Cdc42 GTPases in Cancer.** *Cancer Res.* 2018; **78**(12): 3101–3111.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
42. Gu C, Lee HW, Garborcauskas G, *et al.*: **Dynamin Autonomously Regulates Podocyte Focal Adhesion Maturation.** *J Am Soc Nephrol.* 2017; **28**(2): 446–51.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

# Open Peer Review

Current Peer Review Status:



## Editorial Note on the Review Process

F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

## The reviewers who approved this article are:

### Version 1

1 **Robert Spurney**

<sup>1</sup> Division of Nephrology, Department of Medicine, Duke University Health System, Durham, NC, USA

<sup>2</sup> Durham VA Medical Center, Durham, NC, USA

**Gentzon Hall**

<sup>1</sup> Division of Nephrology, Department of Medicine, Duke University Health System, Durham, NC, USA

<sup>2</sup> Durham VA Medical Center, Durham, NC, USA

**Competing Interests:** No competing interests were disclosed.

2 **Shreeram Akilesh**

Kidney Research Institute, University of Washington, Seattle, Washington, USA

**Competing Interests:** No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

F1000Research